Starting Strength is the bestselling book on the most fundamental and effective approach to strength training ever written. Mark Rippetoe hosts Starting Strength Radio where he discusses topics of interest, primarily to him, but perhaps also to you.
…
continue reading
Inhalt bereitgestellt von Audioboom and Not So Different: a Podcast from The Center for Biosimilars. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Audioboom and Not So Different: a Podcast from The Center for Biosimilars oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
Player FM - Podcast-App
Gehen Sie mit der App Player FM offline!
Gehen Sie mit der App Player FM offline!
S6 Ep4: Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
MP3•Episode-Home
Manage episode 357041818 series 2161808
Inhalt bereitgestellt von Audioboom and Not So Different: a Podcast from The Center for Biosimilars. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Audioboom and Not So Different: a Podcast from The Center for Biosimilars oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
Show notes
Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study
https://www.centerforbiosimilars.com/view/eye-on-pharma-formycon-aflibercept-data-sandoz-chmp-nod-henlius-daratumumab-study
Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab Biosimilars
https://www.centerforbiosimilars.com/view/report-over-60-of-providers-plan-to-only-prescribe-interchangeable-adalimumab-biosimilars
IQVIA: US Spending on Biosimilars to Reach $129 Billion Over Next 5 Years
https://www.centerforbiosimilars.com/view/iqvia-us-spending-on-biosimilars-to-reach-129-billion-over-next-5-years
Vizient Report Predicts Over 3% Inflation Rate for Biologics
https://www.centerforbiosimilars.com/view/vizient-report-predicts-over-3-inflation-rate-for-biologics
On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars
https://www.centerforbiosimilars.com/view/on-the-come-up-what-vizient-s-report-says-about-inflation-and-biosimilars
Patients With RA, IBD Trust Specialists’ Biologic and Biosimilar Recommendations
https://www.centerforbiosimilars.com/view/patients-with-ra-ibd-trust-specialists-biologic-and-biosimilar-recommendations
Study: Higher Adherence Rates Among Users of the Remicade vs Infliximab Biosimilars
https://www.centerforbiosimilars.com/view/study-higher-adherence-rates-among-users-of-the-remicade-vs-infliximab-biosimilars
Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study
https://www.centerforbiosimilars.com/view/eye-on-pharma-formycon-aflibercept-data-sandoz-chmp-nod-henlius-daratumumab-study
Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab Biosimilars
https://www.centerforbiosimilars.com/view/report-over-60-of-providers-plan-to-only-prescribe-interchangeable-adalimumab-biosimilars
IQVIA: US Spending on Biosimilars to Reach $129 Billion Over Next 5 Years
https://www.centerforbiosimilars.com/view/iqvia-us-spending-on-biosimilars-to-reach-129-billion-over-next-5-years
Vizient Report Predicts Over 3% Inflation Rate for Biologics
https://www.centerforbiosimilars.com/view/vizient-report-predicts-over-3-inflation-rate-for-biologics
On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars
https://www.centerforbiosimilars.com/view/on-the-come-up-what-vizient-s-report-says-about-inflation-and-biosimilars
Patients With RA, IBD Trust Specialists’ Biologic and Biosimilar Recommendations
https://www.centerforbiosimilars.com/view/patients-with-ra-ibd-trust-specialists-biologic-and-biosimilar-recommendations
Study: Higher Adherence Rates Among Users of the Remicade vs Infliximab Biosimilars
https://www.centerforbiosimilars.com/view/study-higher-adherence-rates-among-users-of-the-remicade-vs-infliximab-biosimilars
157 Episoden
MP3•Episode-Home
Manage episode 357041818 series 2161808
Inhalt bereitgestellt von Audioboom and Not So Different: a Podcast from The Center for Biosimilars. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Audioboom and Not So Different: a Podcast from The Center for Biosimilars oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
Show notes
Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study
https://www.centerforbiosimilars.com/view/eye-on-pharma-formycon-aflibercept-data-sandoz-chmp-nod-henlius-daratumumab-study
Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab Biosimilars
https://www.centerforbiosimilars.com/view/report-over-60-of-providers-plan-to-only-prescribe-interchangeable-adalimumab-biosimilars
IQVIA: US Spending on Biosimilars to Reach $129 Billion Over Next 5 Years
https://www.centerforbiosimilars.com/view/iqvia-us-spending-on-biosimilars-to-reach-129-billion-over-next-5-years
Vizient Report Predicts Over 3% Inflation Rate for Biologics
https://www.centerforbiosimilars.com/view/vizient-report-predicts-over-3-inflation-rate-for-biologics
On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars
https://www.centerforbiosimilars.com/view/on-the-come-up-what-vizient-s-report-says-about-inflation-and-biosimilars
Patients With RA, IBD Trust Specialists’ Biologic and Biosimilar Recommendations
https://www.centerforbiosimilars.com/view/patients-with-ra-ibd-trust-specialists-biologic-and-biosimilar-recommendations
Study: Higher Adherence Rates Among Users of the Remicade vs Infliximab Biosimilars
https://www.centerforbiosimilars.com/view/study-higher-adherence-rates-among-users-of-the-remicade-vs-infliximab-biosimilars
Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study
https://www.centerforbiosimilars.com/view/eye-on-pharma-formycon-aflibercept-data-sandoz-chmp-nod-henlius-daratumumab-study
Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab Biosimilars
https://www.centerforbiosimilars.com/view/report-over-60-of-providers-plan-to-only-prescribe-interchangeable-adalimumab-biosimilars
IQVIA: US Spending on Biosimilars to Reach $129 Billion Over Next 5 Years
https://www.centerforbiosimilars.com/view/iqvia-us-spending-on-biosimilars-to-reach-129-billion-over-next-5-years
Vizient Report Predicts Over 3% Inflation Rate for Biologics
https://www.centerforbiosimilars.com/view/vizient-report-predicts-over-3-inflation-rate-for-biologics
On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars
https://www.centerforbiosimilars.com/view/on-the-come-up-what-vizient-s-report-says-about-inflation-and-biosimilars
Patients With RA, IBD Trust Specialists’ Biologic and Biosimilar Recommendations
https://www.centerforbiosimilars.com/view/patients-with-ra-ibd-trust-specialists-biologic-and-biosimilar-recommendations
Study: Higher Adherence Rates Among Users of the Remicade vs Infliximab Biosimilars
https://www.centerforbiosimilars.com/view/study-higher-adherence-rates-among-users-of-the-remicade-vs-infliximab-biosimilars
157 Episoden
Alle Folgen
×Willkommen auf Player FM!
Player FM scannt gerade das Web nach Podcasts mit hoher Qualität, die du genießen kannst. Es ist die beste Podcast-App und funktioniert auf Android, iPhone und im Web. Melde dich an, um Abos geräteübergreifend zu synchronisieren.